285 related articles for article (PubMed ID: 18835410)
1. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.
Deyde VM; Okomo-Adhiambo M; Sheu TG; Wallis TR; Fry A; Dharan N; Klimov AI; Gubareva LV
Antiviral Res; 2009 Jan; 81(1):16-24. PubMed ID: 18835410
[TBL] [Abstract][Full Text] [Related]
2. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.
Sheu TG; Deyde VM; Garten RJ; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):354-60. PubMed ID: 19887086
[TBL] [Abstract][Full Text] [Related]
3. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Lackenby A; Democratis J; Siqueira MM; Zambon MC
Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
5. The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Okomo-Adhiambo M; Hurt AC; Gubareva LV
Methods Mol Biol; 2012; 865():95-113. PubMed ID: 22528155
[TBL] [Abstract][Full Text] [Related]
6. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
Duwe S; Schweiger B
J Virol Methods; 2008 Nov; 153(2):134-41. PubMed ID: 18725246
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
[TBL] [Abstract][Full Text] [Related]
8. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
9. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
Qi Y; Fan H; Qi X; Zhu Z; Guo X; Chen Y; Ge Y; Zhao K; Wu T; Li Y; Shan Y; Zhou M; Shi Z; Wang H; Cui L
Virus Res; 2014 Jan; 179():119-24. PubMed ID: 24211668
[TBL] [Abstract][Full Text] [Related]
10. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Bauer K; Richter M; Wutzler P; Schmidtke M
Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
[TBL] [Abstract][Full Text] [Related]
11. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Hurt AC; Okomo-Adhiambo M; Gubareva LV
Methods Mol Biol; 2012; 865():115-25. PubMed ID: 22528156
[TBL] [Abstract][Full Text] [Related]
12. Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.
Barr IG; Deng YM; Iannello P; Hurt AC; Komadina N
Antiviral Res; 2008 Nov; 80(2):200-5. PubMed ID: 18611414
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
14. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.
Ison MG; Gubareva LV; Atmar RL; Treanor J; Hayden FG
J Infect Dis; 2006 Mar; 193(6):760-4. PubMed ID: 16479508
[TBL] [Abstract][Full Text] [Related]
15. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
Ferraris O; Lina B
J Clin Virol; 2008 Jan; 41(1):13-9. PubMed ID: 18055254
[TBL] [Abstract][Full Text] [Related]
16. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
Abed Y; Baz M; Boivin G
J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
[TBL] [Abstract][Full Text] [Related]
17. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Abed Y; Nehmé B; Baz M; Boivin G
Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
[TBL] [Abstract][Full Text] [Related]
18. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Song MS; Marathe BM; Kumar G; Wong SS; Rubrum A; Zanin M; Choi YK; Webster RG; Govorkova EA; Webby RJ
J Virol; 2015 Nov; 89(21):10891-900. PubMed ID: 26292325
[TBL] [Abstract][Full Text] [Related]
19. [Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
Huang L; Zhou JF; Wei H; Shu YL
Bing Du Xue Bao; 2012 Sep; 28(5):572-6. PubMed ID: 23233936
[TBL] [Abstract][Full Text] [Related]
20. [Molecular and genetic analysis of influenza A viruses isolated in Russia, based on the neuraminidase and M2 protein gene sequence].
Rotanov M; Grebennikova TV; Burtseva EI; Shevchenko ES
Mol Gen Mikrobiol Virusol; 2008; (2):27-32. PubMed ID: 18488446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
